Transforming Lung Treatment: Revolutionary Protein Offers Hope for ARDS

A technology invented at University of Maryland, Baltimore, that is focused on treatments for inflammatory diseases, including ARDS, and has been licensed to GEn1E Lifesciences, a biotech company based in Silicon Valley.The technology targets a class of enzymes called kinases — specifically ERK mitogen-activated protein kinases (MAPK) that are important in cancerIt was co-invented by Jeffrey Hasday, MS, the Dr. Herbert Berger Professor of Medicine and division head, pulmonary and critical care medicine, University of Maryland School of Medicine and Paul Shapiro, PhD, professor of pharmaceutical sciences and associate dean of research and advanced graduate studies, University of Maryland School of Pharmacy.#ARDS #BioTechnology #MedSchool #Entrepreneur #PharmacySchool #Research #inventions